These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32178467)

  • 1. Antisense Oligonucleotide in LNA-Gapmer Design Targeting TGFBR2-A Key Single Gene Target for Safe and Effective Inhibition of TGFβ Signaling.
    Kuespert S; Heydn R; Peters S; Wirkert E; Meyer AL; Siebörger M; Johannesen S; Aigner L; Bogdahn U; Bruun TH
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
    Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
    Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts.
    Burel SA; Hart CE; Cauntay P; Hsiao J; Machemer T; Katz M; Watt A; Bui HH; Younis H; Sabripour M; Freier SM; Hung G; Dan A; Prakash TP; Seth PP; Swayze EE; Bennett CF; Crooke ST; Henry SP
    Nucleic Acids Res; 2016 Mar; 44(5):2093-109. PubMed ID: 26553810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
    Uemura Y; Hagiwara K; Kobayashi K
    PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of hepatic transcription profiles of locked ribonucleic acid antisense oligonucleotides: evidence of distinct pathways contributing to non-target mediated toxicity in mice.
    Kakiuchi-Kiyota S; Koza-Taylor PH; Mantena SR; Nelms LF; Enayetallah AE; Hollingshead BD; Burdick AD; Reed LA; Warneke JA; Whiteley LO; Ryan AM; Mathialagan N
    Toxicol Sci; 2014 Mar; 138(1):234-48. PubMed ID: 24336348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
    Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
    J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
    Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
    Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.
    Grünweller A; Wyszko E; Bieber B; Jahnel R; Erdmann VA; Kurreck J
    Nucleic Acids Res; 2003 Jun; 31(12):3185-93. PubMed ID: 12799446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The miR-371∼373 Cluster Represses Colon Cancer Initiation and Metastatic Colonization by Inhibiting the TGFBR2/ID1 Signaling Axis.
    Ullmann P; Rodriguez F; Schmitz M; Meurer SK; Qureshi-Baig K; Felten P; Ginolhac A; Antunes L; Frasquilho S; Zügel N; Weiskirchen R; Haan S; Letellier E
    Cancer Res; 2018 Jul; 78(14):3793-3808. PubMed ID: 29748374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of gapmer antisense oligonucleotide with deoxyribonucleic guanidine (DNG) modifications.
    Kojima N; Shrestha AR; Akisawa T; Piao H; Kizawa H; Ohmiya Y; Kurita R
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):258-269. PubMed ID: 31556356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.
    Castanotto D; Lin M; Kowolik C; Koch T; Hansen BR; Oerum H; Stein CA
    Mol Ther; 2016 Jun; 24(6):1117-1125. PubMed ID: 26961407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical modification study of antisense gapmers.
    Stanton R; Sciabola S; Salatto C; Weng Y; Moshinsky D; Little J; Walters E; Kreeger J; DiMattia D; Chen T; Clark T; Liu M; Qian J; Roy M; Dullea R
    Nucleic Acid Ther; 2012 Oct; 22(5):344-59. PubMed ID: 22852836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transforming growth factor-β plays divergent roles in modulating vascular remodeling, inflammation, and pulmonary fibrosis in a murine model of scleroderma.
    Tsujino K; Reed NI; Atakilit A; Ren X; Sheppard D
    Am J Physiol Lung Cell Mol Physiol; 2017 Jan; 312(1):L22-L31. PubMed ID: 27864286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas.
    Papachristodoulou A; Silginer M; Weller M; Schneider H; Hasenbach K; Janicot M; Roth P
    Clin Cancer Res; 2019 Dec; 25(23):7189-7201. PubMed ID: 31530630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myofibroblast-Specific TGFβ Receptor II Signaling in the Fibrotic Response to Cardiac Myosin Binding Protein C-Induced Cardiomyopathy.
    Meng Q; Bhandary B; Bhuiyan MS; James J; Osinska H; Valiente-Alandi I; Shay-Winkler K; Gulick J; Molkentin JD; Blaxall BC; Robbins J
    Circ Res; 2018 Dec; 123(12):1285-1297. PubMed ID: 30566042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA Reduction and Hepatotoxic Potential Caused by Non-Gapmer Antisense Oligonucleotides.
    Hori SI; Mitsuoka Y; Kugimiya A
    Nucleic Acid Ther; 2019 Feb; 29(1):44-50. PubMed ID: 30508397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of off-target effects of gapmer antisense oligonucleotides using human cells.
    Yoshida T; Naito Y; Yasuhara H; Sasaki K; Kawaji H; Kawai J; Naito M; Okuda H; Obika S; Inoue T
    Genes Cells; 2019 Dec; 24(12):827-835. PubMed ID: 31637814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.